Quarterly and Full-Year Earnings
Q4 net EPS $2.64 and adjusted EPS $1.57; FY2025 net EPS $6.82 and adjusted EPS $7.49. Adjusted EPS in Q4 increased 0.6% year-over-year (ex-FX). Adjusted book value per share (ex-FX) rose 0.5%.
Strong Japan Sales and Product Adoption
Aflac Japan sales increased 15.7% in Q4 and 16% for FY2025. Miraito cancer product drove a remarkable 35.6% sales increase. New medical product Anshin Palette (late Dec) received positive early reception; repriced Tsumitasu supports growth to younger customers.
High Persistency in Japan
Japan premium persistency remained strong at 93.1% for the year, supporting long-term in-force stability despite product introductions and repricing activity.
U.S. New Sales and Premium Growth
Aflac U.S. generated nearly $1.6 billion in new sales in 2025 (over one-third in Q4). Net earned premiums increased ~2.9% for 2025, with Q4 U.S. net earned premiums up 4% and premium persistency remaining strong at 79.2%.
Growing Group and New Channels in U.S.
Group lines and newer channels expanded materially in 2025: network dental up 48.8% YoY, life/absence & disability combined up 11.3%, direct-to-consumer up 10.5%. Group-focused growth initiatives comprised ~20% of new sales.
Capital Return and Dividend Increase
Record 2025 capital deployment: $3.5 billion repurchased (33 million shares) and $1.2 billion in dividends — ~ $4.8 billion returned. Q4 repurchases were $800 million and Q4 dividends $303 million. Board raised Q1 2026 dividend by 5.2%.
Strong Liquidity and Capital Position
Enhanced liquidity via two off-balance-sheet PCAPs adding $2.0 billion of flexibility (undrawn). Holding-company unencumbered liquidity $4.1 billion, $3.1 billion above minimum. Adjusted leverage 21.4% (target 20–25%). SMR above 970%; estimated ESR (with USP) ~253%; combined RBC ~575%.
Solid Investment & Credit Performance
No quarter charge-offs in commercial real estate and no foreclosures recorded. Investment portfolio produced solid net investment income; limited software exposure (~1.5% of portfolio) and diversified middle-market loan exposure.
Profitability Metrics
Adjusted ROE 11.7% (14.5% excluding FX remeasurement). Japan pretax margin 31.3% (only down 30 bps YoY); U.S. pretax margin 17.4% (down 230 bps vs strong prior comparable).
Clear 2026 Guidance Framework
Management reiterated ranges from prior FAB for 2026 (with some refinements): Japan underlying earned premiums expected to decline 1–2%; Japan pretax margin guided to 33–36%; U.S. net earned premium growth expected at lower end of 3–6% and U.S. pretax margin guided 17–20%.